Moderna Inc (MRNA)

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast...

Form 8-K - Current report

Moderna Appoints Michael McDonnell to Board of Directors

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Moderna Science Day Highlights Expanding Potential of mRNA Platform

Provides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation of...

Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc...

Moderna Extends Rally as FDA Advisory Panel Reviews Flu Vaccine Application (MRNA)

Moderna (NASDAQ:MRNA) shares moved higher on Thursday, building on the previous session’s strong gains as investors focused on a key review of...

Form 4 - Statement of changes in beneficial ownership of securities

Moderna to Host Investor Event - Science Day

CAMBRIDGE, MA / ACCESS Newswire / June 17, 2026 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Science Day...

Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028

Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and...

Form 144 - Report of proposed sale of securities

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The INTERCEPT-Lynch trial is...

Form 4 - Statement of changes in beneficial ownership of securities